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Overactive bladder (OAB) is described as urinary
urgency, with or without urge incontinence, and usu-
ally with frequency and nocturia if there is no proven
infection or other obvious pathology [1]. Anticholin-
ergic agents are the most widely used drugs for the
management of neurogenic and idiopathic overactive
detrusor (OAD). The limitations of the current drugs
for the treatment of OAB have lead to a focus on new
targets for pharmacologic intervention and on the
physiologic basis for lower urinary tract function and
dysfunction.
The micturition reflexes involve several transmit-
ters and transmitter systems that may offer therapeutic
targets to control micturition, including γ-aminobutyric
acid, opioids, serotonin, noradrenalin, dopamine and
glutamatergic receptors [2,3]. Glutamate is probably
involved as an excitatory transmitter in the supra-
spinal control pathway between the pontine micturi-
tion center and the preganglionic neurons [4].
Spinal cord injury (SCI) results from secondary
damage via the excitatory amino acid cascade (i.e.
glutamate) or via direct injury to the spinal cord [5].
Glutamate acts on spinal neurons through a variety
of glutamatergic receptor subtypes, including the N-
methyl-D-aspartate (NMDA) subtype, that control the
urogenital reflex pathways at the lumbosacral levels
[6]. Memantine is a specific, noncompetitive NMDA-
receptor antagonist with moderate affinity [7]. Here,
we evaluated the effect of memantine on OAD in rats
with SCI.
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The aim of this study was to determine the effect of memantine on overactive detrusor (OAD) 15
days after spinal cord injury (SCI) in rats. Twenty-eight adult Wistar rats were used in this study.
Fourteen animals served as normal controls, while 14 underwent spinal cord transection (clip
compression technique) at the 10th thoracic vertebra. Fifteen days after SCI, all animals under-
went urodynamic testing to confirm OAD. Memantine (16 mg/kg) was injected intraperitoneally
into rats with SCI and OAD. Parameters measured included voiding volume, micturition pres-
sure, resting bladder pressure, the period between micturitions and the maximum pressure of the
OAD during the filling period. Results have showed that OAD developed in 8/14 animals
(57.1%). OAD was resolved in 5/8 (62.5%) of these animals after memantine administration.
Resting bladder pressure was significantly different in dependent groups (p < 0.05). Micturition
pressure increased after SCI but decreased in rats with SCI after memantine injection. However,
the period between micturitions was prolonged in both SCI and memantine groups, compared
with normal rats. These results show that memantine could be useful for treating neurogenic
OAD after SCI by modulating the micturition reflex pathway. Memantine may also provide an
alternative treatment option for OAD in the future.
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METHODS
Animals
Twenty-eight adult Wistar rats weighing 140–210 g
were used in this study. The University Committee
on Laboratory Animals approved the experimental
protocol.
SCI
Fourteen rats served as normal controls and 14 under-
went spinal cord transection at the 10th thoracic verte-
bra. The animals were anesthetized by intramuscular
injection of ketamine (20 mg/kg body weight). A
midline dorsal incision was made about 2 cm over
the subcutaneous trunk to expose the vertebral spine
and paraspinous muscles. These muscles were split
from their attachment to the spinal processes and
retracted laterally. After laminectomy, a 5-mm gap
was created between the proximal and distal ends.
The spinal cord was compressed by extradural ap-
plication of an aneurismal clip (Technomedical TK
25132.00) for 1 minute. All muscles and skin were
closed using 4-0 catgut sutures. The animals were
treated with intramuscular ampicillin (150 mg/kg)
for 10 days. The bladders of the SCI rats were emptied
manually two times every day.
Urodynamic testing
Fifteen days after SCI, 14 rats underwent a filling 
cystometrogram to confirm OAD, while another 14
served as normal controls. The animals were anes-
thetized with ether inhalation and the bladder was
exposed by a midline abdominal incision. A 6-Fr
double-lumen cystometry catheter (DLC-6P; Life-
tech, Urolab Primus, USA) was implanted into the
bladder through the dome and a suture was tight-
ened around the collar of the catheter. The anatomic
layers were closed using 4-0 catgut sutures. Cystome-
try was started 30 minutes after the surgery to allow
the rats to recover from the ether anesthesia, which
provides a shorter duration of recovery compared
with other anesthetics.
A computer-assisted unit (Life-tech) was used for
urodynamic testing. Cystometric recordings were per-
formed by continuously infusing physiologic saline
(6 mL/hr, Abbott Lifecare infusion pump, Abbott
Lab, Chicago, IL, USA) at room temperature into the
bladder to elicit repetitive voids. After the urody-
namic recordings were completed in the normal and
SCI rats, memantine (16 mg/kg) was administered
intraperitoneally. The effect of memantine on OAD
was observed urodynamically at 40 minutes after
injection.
The parameters measured included voiding vol-
ume, micturition pressure (MP), resting bladder pres-
sure (RBP), the period between micturitions (PM), and
the maximum pressure of the OAD during the filling
period.
Statistical analysis
Data were analyzed using Friedman’s test for three
dependent groups. Wilcoxon signed-rank test was per-
formed to determine the significance of differences
among groups (Bonferroni correction). All data are
shown as mean ± standard deviation and values of
p < 0.05 were considered statistically significant.
RESULTS
Normal rats
The mean RBP was 7.25 ± 3.61 cmH2O (range, 4–
15 cmH2O) and the mean MP was 22.75 ± 9.66 cmH2O
(range, 11–39 cmH2O). PM and voiding volume were
35.75 ± 6.60 seconds (range, 29–49 seconds) and 50–
100μL, respectively (Table). However, the measurement
of voiding volume was not reliable due to technical
problems, including leakage of the small reservoir
placed under the cage. None of these animals
showed OAD (Figure 1A).
SCI rats
Eight of 14 (57.1%) SCI rats had OAD (Figure 1B).
Impaired detrusor contractility was seen in the other
five rats and one rat had hypo-compliant bladder.
The mean RPB in SCI rats with OAD was 14.75 ±
8.24 cmH2O (range, 6–29 cmH2O) 15 days after induc-
ing SCI. Mean MP was 44.37 ± 21.89 cmH2O (range,
20–91 cmH2O) and PM was 48.25 ± 41.32 seconds
(range, 15–140 seconds). The maximum OAD pressure
ranged from 20 to 92 cmH2O in the SCI rats with OAD.
Memantine
After memantine administration, OAD disappeared
in five of the eight SCI rats with OAD (62.5%) (Figure
1C). The maximum OAD pressure decreased in the
remaining three animals. The RBP values were signif-
icantly different among the three groups (p < 0.05), but
Memantine’s effect on overactive detrusor
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there were no statistically significant differences in
terms of MP and PM among the three groups accord-
ing to the results of the Friedman test. RPB and MP
were significantly lower in the memantine group than
in the SCI group according to the Wilcoxon test. The
mean MP, RBP and PM values for each group are
shown in the Table and Figure 2.
DISCUSSION
Memantine has been marketed in Germany since 1982,
and was initially indicated for various neurological
syndromes and cognitive dysfunction. This agent is an
adamantine derivative and blocks ligand-gated Ca2+
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Figure 1. Typical cystometrograms in (A) normal control rats showing no detrusor overactivity; (B) untreated rats with spinal cord
injury showing detrusor overactivity; and (C) rats with SCI after memantine administration showing decreased detrusor pressure.
SCI = Spinal cord injury.
Table. Cystometric parameters in control rats and rats with spinal cord injury before and after memantine treatment
Spinal cord injury group
Control group
Before memantine treatment After memantine treatment
Mean MP (cmH2O) 22.75 ± 9.66 44.37 ± 21.89 30.87 ± 14.74
Mean RBP (cmH2O) 7.25 ± 3.61 14.75 ± 8.24 10.12 ± 7.37
Mean PM (sec) 35.75 ± 6.6 48.25 ± 41.32 65.37 ± 31.25
MP = Micturition pressure; RBP = resting bladder pressure; PM = period between micturitions.
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[7,8]. Glutamate is a major excitatory neurotransmitter
in the mammalian central nervous system. There are
two major classes of glutamate receptors: ionotropic
and metabotropic. The ionotropic glutamate receptors
are classified into three types: NMDA, α-amino-3-
hydroxy-5-methyl-lisoxazole-4-propionic acid (AMPA)
and kainate receptors [9]. NMDA is a large protein
complex, consisting of an ion channel, a number of
binding sites for glutamate, glycine and polyamines,
and a channel blocking site [10].
The function of the NMDA receptor in the micturi-
tion reflex pathway has been extensively studied in
recent years. AMPA/kainate and NMDA glutamate re-
ceptor antagonists decreased the amplitude, frequency
and duration of reflex bladder contractions. In our
study, the PM was prolonged after memantine admin-
istration, consistent with these earlier findings [11].
Conversely, changes in NMDA receptor function were
reported to be involved in the recovery of detrusor–
external urethral sphincter coordination after incom-
plete SCI [12]. Yokoyama et al showed that NMDA
receptors play an essential role in the development of
OAB and that AMPA receptor antagonists temporally
inhibited OAB after cerebral infarction [13].
In the present study, 57.1% of the SCI rats exhibited
OAD 15 days after SCI. This rate is similar to another
study [14]. We observed that OAD was ameliorated by
memantine treatment in 62.5% of these SCI rats. MP was
significantly lower after memantine treatment com-
pared with that seen before memantine administration
in the SCI rats. These results imply that memantine
plays a role in decreasing detrusor contractility. This
effect may be due to blocking the ligand-gated Ca2+
channels that decrease intracellular Ca2+ levels [15,16].
Anticholinergic agents are currently recommended






















































Figure 2. Comparison of cystometric parameters between differ-
ent group of rats. (A) Mean micturition pressure; (B) Mean rest-
ing bladder pressure; (C) Mean period between micturitions.
SCI = Spinal cord injury; MP = micturition pressure; RBP = rest-
ing bladder pressure; PM = period between micturitions.
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agents are clinically effective for the relief of OAB
symptoms, their use has been associated with adverse
effects such as dry mouth, constipation and blurred
vision [17]. Furthermore, these agents can have a
negative effect on cognitive function, particularly in
the elderly [18]. For these reasons, other agents with
fewer adverse effects are needed for the treatment of
OAB. Although the effect of memantine on OAB is
not fully understood, our study showed that meman-
tine has a positive effect on OAB. Conversely, ad-
verse effects of NMDA receptor antagonists, such as
locomotor stimulation, ataxia, cognitive impairment
and psychotomimetic actions, have been described
[19]. Nevertheless, these effects of memantine occur
at much higher doses [20].
In conclusion, the administration of memantine
reduced bladder contraction pressure in rats. Thus
memantine offers an effective treatment for OAD
after SCI. This drug may provide alternative options
for the treatment of OAB. Further studies are now
needed to confirm the effect of memantine on OAB in
clinical trials.
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